High Doses of Botulinum Toxin Type A for the Treatment of Post-Stroke Spasticity: Rationale for a Real Benefit for the Patients

In the past few years, there was a great interest in the use of higher doses of botulinum toxin type A, especially in case of upper and lower limb severe spasticity. To date, only one prospective, non-randomized, single-arm, multicenter, open-label, dose-titration study with the employment of incobotulinum toxin up to 800 U has been published, and the authors investigated safety and tolerability. Other researches showed efficacy in spasticity reduction, but there is a lack of evidence about the reasons to use high doses of botulinum toxin. This short communication highlights the benefits of higher doses for subjects with upper and lower limb spasticity.

Automated summary

In recent years, there has been increasing interest in using higher doses of botulinum toxin type A for severe spasticity in the upper and lower limbs. While one study has investigated the safety and tolerability of using a dose of up to 800 U, there is limited evidence on the reasons for using high doses of botulinum toxin. This short communication highlights the benefits of higher doses for individuals with upper and lower limb spasticity.